Advanced search
Publication Cover
Future Cardiology Volume 6, 2010 - Issue 2
Submit an article Journal homepage
231
Views
1
CrossRef citations to date
0
Altmetric
Review

Factors Associated with Clopidogrel Nonresponsiveness

Kathryn M Momarya Mercer University College of Pharmacy and Health Sciences Department of Pharmacy Practice 3001 Mercer University DriveAtlantaGA30341USA Tel.: +1 678 547 6218 Fax: +1 678 547 [email protected]Correspondence[email protected]
&
Michael P Dorschb Department of Pharmacy Services University of Michigan Health System and Department of Clinical Social & Administrative Sciences University of Michigan College of PharmacyAnn ArborMIUSA Tel.: +1 734 763 5576 Fax: +1 734 936 [email protected]
Pages 195-210 | Published online: 15 Mar 2010

Bibliography

  • A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 348(9038), 1329–1339 (1996).
  • Yusuf S , ZhaoF, MehtaSRet al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.N. Engl. J. Med., 345(7), 494–502 (2001).
  • Steinhubl SR , BergerPB, MannJTet al. 3rd : Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA, 288(19), 2411–2420 (2002).
  • Anderson JL , AdamsCD, AntmanEMet al.: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.J. Am. Coll. Cardiol., 50(7), E1–E157 (2007).
  • King SB et al. 3rd, Smith SC Jr, Hirshfeld JW Jr : 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J. Am. Coll. Cardiol., 51(2), 172–209 (2008).
  • Gurbel PA , BeckerRC, MannKG, SteinhublSR, MichelsonAD: Platelet function monitoring in patients with coronary artery disease.J. Am. Coll. Cardiol., 50(19), 1822–1834 (2007).
  • Price MJ : Bedside evaluation of thienopyridine antiplatelet therapy.Circulation, 119(19), 2625–2632 (2009).
  • Trenk D , HochholzerW, FrommMFet al.: Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.J. Am. Coll. Cardiol., 51(20), 1925–1934 (2008).
  • Marcucci R , GoriAM, PanicciaRet al.: Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.Circulation, 119(2), 237–242 (2009).
  • Barsky AA , AroraRR: Clopidogrel resistance: myth or reality?J. Cardiovasc. Pharmacol. Ther., 11(1), 47–53 (2006).
  • Kuliczkowski W , WitkowskiA, PolonskiLet al.: Interindividual variability in the response to oral antiplatelet drugs: a position paper of the working group on antiplatelet drugs resistance appointed by the section of cardiovascular interventions of the polish cardiac society, endorsed by the working group on thrombosis of the european society of cardiology.Eur. Heart J., 30(4), 426–435 (2009).
  • Caplain H , DonatF, GaudC, NecciariJ: Pharmacokinetics of clopidogrel.Semin. Thromb. Hemost., 25(Suppl.), 225–228 (1999).
  • DuBuske LM : The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions.Drug Saf., 28(9), 789–801 (2005).
  • Mega JL , CloseSL, WiviottSDet al.: Cytochrome p-450 polymorphisms and response to clopidogrel.N. Engl. J. Med., 360(4), 354–362 (2009).
  • Desta Z , ZhaoX, ShinJG, FlockhartDA: Clinical significance of the cytochrome P450 2C19 genetic polymorphism.Clin. Pharmacokinet., 41(12), 913–958 (2002).
  • Ingelman-Sundberg M , SimSC, GomezA, Rodriguez-AntonaC: Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.Pharmacol. Ther., 116(3), 496–526 (2007).
  • Kuehl P , ZhangJ, LinYet al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.Nat. Genet., 27(4), 383–391 (2001).
  • Savi P , PereilloJM, UzabiagaMFet al.: Identification and biological activity of the active metabolite of clopidogrel.Thromb. Haemost., 84(5), 891–896 (2000).
  • Erlinge D , VarenhorstC, BraunOOet al.: Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.J. Am. Coll. Cardiol., 52(24), 1968–1977 (2008).
  • Matetzky S , FeferP, ShenkmanB, VaronD, SavionN, HodH: Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction.Am. J. Cardiol., 102(5), 524–529 (2008).
  • Kim KA , ParkPW, HongSJ, ParkJY: The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.Clin. Pharmacol. Ther., 84(2), 236–242 (2008).
  • Hulot JS , BuraA, VillardEet al.: Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.Blood, 108(7), 2244–2247 (2006).
  • Varenhorst C , JamesS, ErlingeDet al.: Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.Eur. Heart J., 30(14), 1744–1752 (2009).
  • Frere C , CuissetT, MorangePEet al.: Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.Am. J. Cardiol., 101(8), 1088–1093 (2008).
  • Geisler T , SchaeffelerE, DipponJet al.: CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.Pharmacogenomics, 9(9), 1251–1259 (2008).
  • Gladding P , WebsterM, ZengIet al.: The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (plavix response in coronary intervention) trial.JACC Cardiovasc. Interv., 1(6), 620–627 (2008).
  • Giusti B , GoriAM, MarcucciRet al.: Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.Pharmacogenet. Genomics, 17(12), 1057–1064 (2007).
  • Collet JP , HulotJS, PenaAet al.: Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.Lancet, 373(9660), 309–317 (2009).
  • Simon T , VerstuyftC, Mary-KrauseMet al.: Genetic determinants of response to clopidogrel and cardiovascular events.N. Engl. J. Med., 360(4), 363–375 (2009).
  • Sibbing D , StegherrJ, LatzWet al.: Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.Eur. Heart J., 30(8), 916–922 (2009).
  • Giusti B , GoriAM, MarcucciRet al.: Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.Am. J. Cardiol., 103(6), 806–811 (2009).
  • Shuldiner AR , O‘ConnellJR, BlidenKPet al.: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.JAMA, 302(8), 849–857 (2009).
  • Mega JL , ThakuriaJV, CannonCP, SabatineMS: Sequence variations in CYP metabolism genes and cardiovascular outcomes following treatment with clopidogrel: insights from the CLARITY-TIMI 28 genomic study.J. Am. Coll. Cardiol., 51(10), A206 (2008).
  • Smith SM , JudgeHM, PetersGet al.: Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.Platelets, 17(4), 250–258 (2006).
  • Angiolillo DJ , Fernandez-OrtizA, BernardoEet al.: Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel.Arterioscler. Thromb. Vasc. Biol., 26(8), 1895–1900 (2006).
  • Suh JW , KooBK, ZhangSYet al.: Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.CMAJ, 174(12), 1715–1722 (2006).
  • Taubert D , vonBeckerathN, GrimbergGet al.: Impact of P-glycoprotein on clopidogrel absorption.Clin. Pharmacol. Ther., 80(5), 486–501 (2006).
  • Ziegler S , SchillingerM, FunkMet al.: Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease.Stroke, 36(7), 1394–1399 (2005).
  • Cuisset T , FrereC, QuiliciJet al.: Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.Thromb. Res., 120(6), 893–899 (2007).
  • Angiolillo DJ , Fernandez-OrtizA, BernardoEet al.: Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.Thromb. Res., 116(6), 491–497 (2005).
  • Lau WC , WaskellLA, WatkinsPBet al.: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug–drug interaction.Circulation, 107(1), 32–37 (2003).
  • Mukherjee D , Kline-RogersE, FangJ, MunirK, EagleKA: Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome.Heart, 91(1), 23–26 (2005).
  • Saw J , SteinhublSR, BergerPBet al.: Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.Circulation, 108(8), 921–924 (2003).
  • Saw J , BrennanDM, SteinhublSRet al.: Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial.J. Am. Coll. Cardiol., 50(4), 291–295 (2007).
  • Siller-Matula JM , SpielAO, LangIM, KreinerG, ChristG, JilmaB: Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel.Am. Heart J., 157(1), 148. E1–148.E5 (2009).
  • Gilard M , ArnaudB, CornilyJCet al.: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (omeprazole clopidogrel aspirin) study.J. Am. Coll. Cardiol., 51(3), 256–260 (2008).
  • Ho PM , MaddoxTM, WangLet al.: Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.JAMA, 301(9), 937–944 (2009).
  • Juurlink DN , GomesT, KoDTet al.: A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.CMAJ, 180(7), 713–718 (2009).
  • Stanek EJ , AubertRE, KreutzRP, YaoJ, FlockhartDA, EpsteinRS: A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: the Clopidogrel Medco Outcomes study. Presented at: 32nd Annual Scientific Sessions of the Society of Cardiovascular Angiography and Intervention. Las Vagas, NV, USA, 6–9 May 2009 (Abstract O–11).
  • O‘Donoghue ML , BraunwaldE, AntmanEMet al.: Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.Lancet, 374(9694), 989–997 (2009).
  • Dunn SP , MacaulayTE, BrennanDMet al.: Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial.Circulation, 118(18), 118S–815S (2008).
  • Ramirez JF , SelzerF, ChakapraniRet al.: Proton pump inhibitor and clopidogrel combination is not associated with adverse clinical outcomes after PCI: the NHLBI dynamic registry.J. Am. Coll. Cardiol., 53(10), A27 (2009).
  • Tsiaousis GZ , ZairiaMN, PatsourakosNet al.: Oral proton pump inhibitors and their impact on the effectiveness of dual anti-platelet therapy during the first year after elective coronary stenting.J. Am. Coll. Cardiol., 53(10), A335 (2009).
  • Sabatine MS , CannonCP, GibsonCMet al.: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.N. Engl. J. Med., 352(12), 1179–1189 (2005).
  • Chen ZM , JiangLX, ChenYPet al.: Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.Lancet, 366(9497), 1607–1621 (2005).
  • Angiolillo DJ , Fernandez-OrtizA, BernardoEet al.: Platelet function profiles in patients with Type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.Diabetes, 54(8), 2430–2435 (2005).
  • Angiolillo DJ , BernardoE, RamirezCet al.: Insulin therapy is associated with platelet dysfunction in patients with Type 2 diabetes mellitus on dual oral antiplatelet treatment.J. Am. Coll. Cardiol., 48(2), 298–304 (2006).
  • Motovska Z , WidimskyP, PetrRet al.: Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin‘s advantage and the smoking “paradox”.J. Cardiovasc. Pharmacol., 53(5), 368–372 (2009).
  • Ferroni P , BasiliS, FalcoA, DaviG: Platelet activation in Type 2 diabetes mellitus.J. Thromb. Haemost., 2(8), 1282–1291 (2004).
  • Angiolillo DJ , SuryadevaraS: Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus.Best Pract. Res. Clin. Endocrinol. Metab., 23(3), 375–388 (2009).
  • Angiolillo DJ , ShoemakerSB, DesaiBet al.: Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study.Circulation, 115(6), 708–716 (2007).
  • Aleil B , LeonC, CazenaveJP, GachetC: CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring.J. Thromb. Haemost., 7(10), 1747–1749 (2009).
  • Angiolillo DJ , Fernandez-OrtizA, BernardoEet al.: Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?J. Invasive Cardiol., 16(4), 169–174 (2004).
  • Sibbing D , von Beckerath O, Schomig A, Kastrati A, von Beckerath N: Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am. J. Cardiol., 100(2), 203–205 (2007).
  • Bliden KP , DichiaraJ, LawalLet al.: The association of cigarette smoking with enhanced platelet inhibition by clopidogrel.J. Am. Coll. Cardiol., 52(7), 531–533 (2008).
  • Wilhelmsson C , VedinJA, ElmfeldtD, TibblinG, WilhelmsenL: Smoking and myocardial infarction.Lancet, 1(7904), 415–420 (1975).
  • Desai NR , MegaJL, JiangS, CannonCP, SabatineMS: Interaction between cigarette smoking and clinical benefit of clopidogrel.J. Am. Coll. Cardiol., 53(15), 1273–1278 (2009).
  • Aleil B , JacqueminLet al., De Poli F : Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (vasodilator-stimulated phosphoprotein-02) randomized study. JACC Cardiovasc. Interv., 1(6), 631–638 (2008).
  • Angiolillo DJ , CostaMA, ShoemakerSBet al.: Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment.Am. J. Cardiol., 101(4), 440–445 (2008).
  • Bonello L , Camoin-JauL, ArquesSet al.: Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study.J. Am. Coll. Cardiol., 51(14), 1404–1411 (2008).
  • Gurbel PA , BlidenKP, ZamanKA, YohoJA, HayesKM, TantryUS: Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the clopidogrel loading with eptifibatide to arrest the reactivity of platelets (CLEAR PLATELETS) study.Circulation, 111(9), 1153–1159 (2005).
  • Pena A , ColletJP, HulotJSet al.: Can we override clopidogrel resistance.Circulation, 119(21), 2854–2857 (2009).
  • Wiviott SD , BraunwaldE, McCabeCHet al.: Prasugrel versus clopidogrel in patients with acute coronary syndromes.N. Engl. J. Med., 357(20), 2001–2015 (2007).
  • Aleil B , RochouxG, MonassierJP, CazenaveJP, GachetC: Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases.J. Thromb. Haemost., 5(4), 879–881 (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.